News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Visient Therapeutics, Inc. Appoints Ophthalmologist David A. Saperstein To Scientific Advisory Board


10/19/2005 5:13:01 PM

SEATTLE, March 15 /PRNewswire/ -- Visient Therapeutics announced today that Dr. David A. Saperstein, Associate Professor of Ophthalmology at the University of Washington, has joined its Scientific Advisory Board.

Dr. Saperstein is a practicing ophthalmologist and an Associate Professor of Ophthalmology at the University of Washington in Seattle. Prior to this, he was an Assistant Professor of Ophthalmology at Emory University. Dr. Saperstein specializes in the medical and surgical treatment of retinal diseases and has a special interest in the treatment of age-related macular degeneration (AMD) and inherited retinal diseases. Dr. Saperstein has served as a primary investigator in several FDA pharmaceutical Phase 1, 2 and 3 clinical trials for AMD and other vision threatening disorders. Due to his experience in the field he has become a key opinion leader in the field of pharmaceutical treatments for retinal disease. Dr. Saperstein earned a B.S. in Electrical Engineering at George Washington University and his M.D. at Pennsylvania State University. He completed his residency at Saint Louis University School of Medicine and a fellowship in Vitreoretinal Medicine and Surgery at Emory University. Dr. Saperstein is board certified by the American Board of Ophthalmology and a member of the Macula Society, Retina Society and American Society of Retina Specialists.

"Dr. Saperstein has a track record in building pioneering clinical programs and demonstrating how new techniques can advance human health. We add his clinical wisdom in macular degeneration to an advisory panel of world- class experts," said Albert Luderer, Ph.D., President, Visient Therapeutics, and President and CEO of parent company, Light Sciences. "As people grow older, their hope is to maintain their independence, and macular degeneration is among the leading causes of blindness -- the polar opposite of personal independence. Dr. Saperstein joins with us to tackle this pressing health issue," he added.

Dr. Saperstein joins incumbent ophthalmic experts on the Board, including ophthalmic laser and AMD pioneer Professor John Marshall, eminent ophthalmic surgeon and expert in diabetic retinopathy Peter Hamilton, and macular degeneration specialist and Founder and President of the Macula Foundation Dr. Lawrence A. Yannuzzi.

About Visient Therapeutics

Visient Therapeutics is wholly owned subsidiary of Light Sciences Corporation. Light Sciences Corporation, founded in 1995, is a privately owned company developing Light Infusion Technology (Litx), a proprietary combination product comprising a photoreactive agent (LS11) activated by non-coherent light infusion devices. Litx represents an important step forward in the clinical application of light activated drugs in cancer, cardiovascular, eye and many other diseases. For additional information about Light Sciences, please visit http://www.lightsciences.com/.

NOTE: Light Sciences(R), Litx(TM) and Light Infusion Technology(TM) are registered or proprietary marks of Light Sciences Corporation.

Contact: Al Luderer President and CEO Visient Therapeutics 425-369-2800 info@lightsci.com Evelyn Sprigg Makovsky & Co. 212-508-9614 esprigg@makovsky.com

Visient Therapeutics

CONTACT: Al Luderer, President and CEO of Visient Therapeutics,+1-425-369-2800, or info@lightsci.com; or Evelyn Sprigg of Makovsky & Co.,+1-212-508-9614, or esprigg@makovsky.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES